Table 2.
Group | n | Week 2 |
Week 6 |
Week 8 |
|||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
TG, mM | LDL-C, mM | HDL-C, mM | CHOL, mM | TG, mM | LDL-C, mM | HDL-C, mM | CHOL, mM | TG, mM | LDL-C, mM | HDL-C, mM | CHOL, mM | ||
Control group | 8 | 0.63 ± 0.17 | 0.24 ± 0.08 | 0.96 ± 0.18 | 1.50 ± 0.33 | 0.60 ± 0.16 | 0.23 ± 0.06 | 0.96 ± 0.15 | 1.72 ± 0.27 | 0.66 ± 0.20 | 0.20 ± 0.11 | 1.20 ± 0.28 | 1.30 ± 0.23 |
Model group | 7 | 0.69 ± 0.18 | 0.30 ± 0.07 | 1.04 ± 0.09 | 1.63 ± 0.27 | 0.59 ± 0.17 | 0.20 ± 0.07 | 1.35 ± 0.22 | 2.42 ± 0.34* | 0.79 ± 0.18 | 0.31 ± 0.07 | 1.44 ± 0.29 | 2.33 ± 0.21* |
Positive control group | 7 | 0.64 ± 0.12 | 0.26 ± 0.05 | 1.01 ± 0.15 | 1.52 ± 0.24 | 0.52 ± 0.18 | 0.24 ± 0.11 | 1.24 ± 0.22 | 2.00 ± 0.31 | 0.63 ± 0.20 | 0.25 ± 0.04 | 1.30 ± 0.23 | 1.92 ± 0.14## |
High-dose group | 6 | 0.78 ± 0.26 | 0.24 ± 0.06 | 0.99 ± 0.14 | 1.61 ± 0.25 | 0.70 ± 0.24 | 0.24 ± 0.16 | 1.38 ± 0.37 | 2.23 ± 0.57 | 0.88 ± 0.36 | 0.22 ± 0.08 | 1.19 ± 0.19 | 1.81 ± 0.20## |
Moderate- dose group | 6 | 0.71 ± 0.19 | 0.29 ± 0.07 | 1.03 ± 0.21 | 1.66 ± 0.29 | 0.72 ± 0.23 | 0.25 ± 0.08 | 1.35 ± 0.22 | 2.21 ± 0.36 | 0.81 ± 0.18 | 0.34 ± 0.08 | 1.33 ± 0.31 | 2.04 ± 0.26# |
Low-dose group | 6 | 0.68 ± 0.22 | 0.28 ± 0.09 | 0.95 ± 0.16 | 1.58 ± 0.37 | 0.51 ± 0.11 | 0.26 ± 0.11 | 1.37 ± 0.28 | 2.33 ± 0.37 | 0.78 ± 0.27 | 0.28 ± 0.13 | 1.35 ± 0.26 | 1.95 ± 0.27## |
Data presented as mean ± SD.
P < 0.01 versus control group; #P < 0.05 versus model group; ##P < 0.01 versus model group; analysis of variance and Q test.
TG, triglyceride; LDL-C low-density lipoprotein cholesterol; HDL-C, high-density lipoprotein cholesterol; CHOL, cholesterol.